How much bacteriostatic water with tirzepatide?
Most research-handling protocols use 2 mL of bacteriostatic water per 10 mg tirzepatide vial, yielding a 5 mg/mL working concentration. Doses in the published clinical-trial range (2.5-15 mg per week) require relatively large per-draw volumes; the 2 mL fill is the typical choice because it keeps per-dose syringe volumes practical without making the lower doses too small to measure accurately.
What the research literature says
Tirzepatide is supplied as a lyophilised powder in a sealed vial under inert gas. The clinical-trial dose range across the SURPASS and SURMOUNT programs spans 2.5 mg to 15 mg per week (PMID 32730231, PMID 34170647), with weekly subcutaneous administration supported by the compound’s ~5-day plasma half-life.
For a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg/mL): a 2.5 mg dose draws 50 units on an insulin syringe; 5 mg draws 100 units (the full barrel of a 1 mL insulin syringe); higher doses split across multiple draws or use larger-barrel syringes. Reconstituting with 1 mL instead (10 mg/mL) halves the per-dose volume requirement but reduces the precision available for the lower-dose ends of the experimental range.
The lyophilization-stability literature (PMID 10967427, PMID 15032301) consolidates the framework for post-reconstitution stability — reconstituted tirzepatide in bacteriostatic water at 2-8 °C is typically referenced to a 28-day in-use stability window, aligned with the antimicrobial protection profile of the 0.9% benzyl alcohol preservative.
Why this matters in research context
The reconstitution-volume choice ties directly to the experimental dose-titration range. Researchers running a multi-week dose-escalation protocol (typical SURMOUNT pattern: start 2.5 mg, escalate by 2.5 mg every 4 weeks toward a 10-15 mg maintenance) need enough volume precision at the low-dose end to draw accurate single-digit milligram doses. The 2 mL fill is the standard pick because it balances precision at 2.5 mg with practical syringe volumes at 10 mg. The full reconstitution-math protocol with syringe-IU conversion tables is consolidated in the reconstitution guide.
Related compounds
- Tirzepatide 10mg — the compound covered by this answer
- Semaglutide 10mg — parallel long-acting incretin agonist; reconstitution math identical at the per-vial level
- Tirzepatide (glossary entry) — receptor pharmacology, clinical-trial overview
Related research questions
- How long does reconstituted tirzepatide last?
- What is the half-life of tirzepatide?
- How much bacteriostatic water with semaglutide?
References
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5(17):e140532. [PMID 32730231]
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385(6):503-515. [PMID 34170647]
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203(1-2):1-60. [PMID 10967427]
- Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res 2004;21(2):191-200. [PMID 15032301]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Tirzepatide is sold strictly as a research-grade reagent for laboratory and bench research applications.